Novel perspectives for the treatment of gastric cancer: From a global approach to a personalized strategy

Current Oncology Reports

Volumn 12, Issue 3, 2010, Pages 175-185

  Scartozzi, Mario ^a   Pistelli, Mirco ^a   Bittoni, Alessandro ^a   Giampieri, Riccardo ^a   Galizia, Eva ^b   Berardi, Rossana ^a   Faloppi, Luca ^a   Del Prete, Michela ^a   Cascinu, Stefano ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b Ospedale Profili   (Italy)

Author keywords

Adjuvant; Antibody; Biological; Cancer; Chemotherapy; Drug; Gastric; Metastatic; Neoadjuvant; Perioperative; TKI

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; LAPATINIB; MARIMASTAT; MATUZUMAB; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; SORAFENIB; SUNITINIB; TRASTUZUMAB; UNINDEXED DRUG;

ADVANCED CANCER; ANOREXIA; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; CHEMOSENSITIZATION; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; GASTRECTOMY; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; REVIEW; STOMACH ADENOCARCINOMA; STOMACH CANCER; TREATMENT DURATION; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; GASTRECTOMY; HUMANS; INDIVIDUALIZED MEDICINE; RADIOTHERAPY DOSAGE; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 77952240483     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-010-0101-8     Document Type: Review

References (49)

1. J Hermans JJ Bonekamp MC Bon, et al. 1993 Adjuvant therapy after resection for gastric cancer: meta-analysis of randomized trials J Clin Oncol 11 1441 1447 1:STN:280:DyaK3szivFCrtw%3D%3D 8336183 (Pubitemid 23228247)
2. Earle CC, Maroun JA: Adjuvant chemotherapy after resection for gastric cancer in non-Asian patients. Revisiting a meta-analysis of randomized trials. Eur J Cancer 1999, 35:1059-1064.
3. M Mari I Floriani A Tinazzi, et al. 2000 Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis for published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente) Ann Oncol 11 837 843 10.1023/A:1008377101672 1:STN:280:DC%2BD3cvks1SgtA%3D%3D 10997811
4. I Panzini L Gianni PP Fattori, et al. 2002 Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses Tumori 88 21 27 1:CAS:528:DC%2BD38Xjt1ChtLo%3D 12004845 (Pubitemid 34269794)
5. F Di Costanzo S Gasperoni L Manzione, et al. 2008 Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC J Natl Cancer Inst 100 388 398 10.1093/jnci/djn054 18334706 (Pubitemid 351480516)
6. O Bouche M Ychou P Burtin, et al. 2005 Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801) Ann Oncol 16 1488 1497 10.1093/annonc/mdi270 1:STN:280:DC%2BD2MvjvVaisw%3D%3D 15939717 (Pubitemid 41226403)
7. E Bajetta R Buzzoni L Mariani, et al. 2002 Adjuvant chemotherapy in gastric cancer: 5-year results of a randomized study by the Italian Trials in Medical Oncology (ITMO) Group Ann Oncol 13 299 307 10.1093/annonc/mdf040 1:STN:280:DC%2BD387ltl2guw%3D%3D 11886009 (Pubitemid 34704984)
8. Cascinu S, La bianca R, Barone C, et al.: Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. J Natl Cancer Inst 2007, 99:601-607. (Pubitemid 47073541)
9. • Buyse ME, Pignon J: Meta-analyses of randomized trials assessing the interest of postoperative adjuvant chemotherapy and prognostic factors in gastric cancer. J Clin Oncol 2009, 27(Suppl 15):abstract 4539. This is the latest meta-analysis available about adjuvant treatment of gastric cancer. A small, but definite improvement in OS has been suggested, along with a tumor stage-related beneficial effect deriving from chemotherapy.
10. JS Macdonald SR Smalley J Benedetti, et al. 2001 Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction N Engl J Med 345 725 730 10.1056/NEJMoa010187 1:STN:280:DC%2BD3Mvps1Cqug%3D%3D 11547741
11. Macdonald JS, Benedetti J, Smalley S, et al.: Chemoradiation of resected gastric cancer: A 10-year follow-up of the phase III trial INT0116 (SWOG 9008). J Clin Oncol 2009, 27(Suppl 15):abstract 4515.
12. M Scartozzi E Galizia F Graziano, et al. 2005 Over-D1 dissection may question the value of radiotherapy as a part of an adjuvant programme in high-risk radically resected gastric cancer patients Br J Cancer 92 1051 1054 10.1038/sj.bjc.6602468 1:STN:280:DC%2BD2M7ltFCitQ%3D%3D 15770210 (Pubitemid 40546668)
13. D Cunningham WH Allum SP Stenning, et al. 2006 MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer N Engl J Med 355 11 20 10.1056/NEJMoa055531 1:CAS:528: DC%2BD28Xms1Chsrw%3D 16822992
14. Boige V, Pignon J, Saint-Aubert B, et al.: Final results of randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of the stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. ASCO 2007, abstract 4510.
15. Roth et al.: Comparative evaluation in tolerance of neoadjuvant versus adjuvant docetaxel based chemotherapy in resectable gastric cancer in a randomized trial of the Swiss Group for Clinical Cancer Research (SAKK) and the European Institute of Oncology (EIO). Presented at the World Congress on Gastrointestinal Cancer. Barcelona, Spain; June 28-July 1, 2007.
16. Schuhmacher C, Schlag P, Lordick F, et al.: Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardia: randomized EORTC phase III trial #40954. J Clin Oncol 2009, 27(Suppl 15):abstract 4510.
17. M Stahl KM Walz M Stuschke, et al. 2009 Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction J Clin Oncol 27 851 856 10.1200/JCO.2008.17.0506 1:CAS:528:DC%2BD1MXjs1Kntrw%3D 19139439
18. D Cunningham N Starling S Rao, et al. 2008 Capecitabine and oxaliplatin for advanced esophagogastric cancer N Engl J Med 358 36 46 10.1056/NEJMoa073149 1:CAS:528:DC%2BD1cXisFSktg%3D%3D 18172173
19. YK Kang WK Kang DB Shin, et al. 2009 Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial Ann Oncol 20 667 673
20. • Koizumi W, Narahara H, Hara T, et al.: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008, 9:215-221. This phase 3 randomized trial demonstrated the superiority of combined cisplatin-S1 over S1 in a Japanese population.
21. HJ Lenz FC Lee DG Haller, et al. 2007 Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study Cancer 109 33 40 10.1002/cncr.22329 1:CAS:528:DC%2BD2sXhtVKrtLc%3D 17133415 (Pubitemid 46120192)
22. • Ajani JA, Rodriquez W, Bodoky G, et al.: Randomized phase III trial for first line treatment of advanced gastric cancer. Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS) [abstract 8]. Presented at 2009 Gastrointestinal Cancers Symposium, ASCO. San Francisco, CA; January 15-17, 2009. In this trial, cisplatin/S1 combination demonstrated an equivalent efficacy compared to cisplatin/5-FU, with an improved toxicity profile.
23. N Bozu S Yamamoto H Fukuda, et al. 2009 Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study Lancet Oncol 10 1063 1069 10.1016/S1470-2045(09)70259-1
24. J Ajani VM Moiseyenko S Tjulandin, et al. 2007 Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 study group J Clin Oncol 25 3210 3216 10.1200/JCO.2006.08.3956 1:CAS:528:DC%2BD2sXhtVWqs7rN 17664468 (Pubitemid 47325603)
25. Tebbutt NC, Cummins MM, Sourjina T, et al.: Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. Br J Cancer 2010, In press.
26. J Capdevila E Elez T Macarulla, et al. 2009 Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment Cancer Treat Rev 35 354 363 10.1016/j.ctrv.2009.02.001 1:CAS:528:DC%2BD1MXmtlOqtr0%3D 19269105
27. C Pinto F Di Fabio C Barone, et al. 2009 Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study) Br J Cancer 101 1261 1268 10.1038/sj.bjc.6605319 1:CAS:528:DC%2BD1MXht1GntbnN 19773760
28. F Lordick S Lorenzen S Hegewisch-Becker, et al. 2007 Cetuximab plus weekly oxaliplatin/5FU/FA (FUFOX) in 1st line metastatic gastric cancer. Final results from a multicenter phase II study of the AIO upper GI study group [abstract] J Clin Oncol 25 Suppl 18 4526
29. SW Han DY Oh SA Im, et al. 2009 Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer Br J Cancer 100 298 304 10.1038/sj.bjc.6604861 1:CAS:528:DC%2BD1MXpsVSrtg%3D%3D 19127259
30. Kim C, Lee JL, Ryu MH, et al.: A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. Invest New Drugs 2009 Dec 9 (Epub ahead of print).
31. Woell E, Greil R, Eisterer W, et al.: Oxaliplatin, irinotecan, and cetuximab in advanced gastric cancer. First efficacy results of a multicenter phase II trial (AGMT Gastric-2) of the Arbeitsgemeinschaft Medikamentoese Tumortherapie (AGMT) [abstract]. J Clin Oncol (Meeting Abstracts) 2009, 27:4538.
32. C Pinto F Di Fabio S Siena, et al. 2007 Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study) Ann Oncol 18 510 517 10.1093/annonc/mdl459 1:STN:280:DC%2BD2s7hsVKjsA%3D%3D 17164226 (Pubitemid 46359631)
33. S Kanzler T Trarbach T Seufferlein, et al. 2009 Cetuximab with irinotecan/folinic acid/5-FU as first-line treatment in advanced gastric cancer: A nonrandomized multicenter AIO phase II study [abstract] J Clin Oncol (Meeting Abstracts) 27 4534
34. K Yeh C Hsu C Hsu, et al. 2009 Phase II study of cetuximab plus weekly cisplatin and 24-hour infusion of high-dose 5-fluorouracil and leucovorin for the first-line treatment of advanced gastric cancer [abstract] J Clin Oncol (Meeting Abstracts) 27 4567
35. http://www.clinicaltrials.gov Accessed January 11, 2010.
36. S Rao N Starling D Cunningham, et al. 2008 Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer Br J Cancer 99 868 874 10.1038/sj.bjc.6604622 1:CAS:528:DC%2BD1cXhtV2jurvK 19238629
37. Doi T, Koizumi W, Siena S, et al.: Efficacy, tolerability and pharmacokinetics of gefitinib (Iressa, ZD1839) in pretreated patients with metastatic gastric cancer. Proc ASCO 2004, abstract 1036.
38. T Dragovich S McCoy SG Urba, et al. 2006 Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127 J Clin Oncol 24 4922 4927 10.1200/JCO.2006.07.1316 1:CAS:528:DC%2BD28Xht1eiu73L 17050876 (Pubitemid 46630921)
39. M Tanner M Hollmen TT Junttila, et al. 2005 Amplification of HER-2 in gastric carcinoma: association with topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab Ann Oncol 16 273 278 10.1093/annonc/mdi064 1:STN:280:DC%2BD2M%2FjvFyhsg%3D%3D 15668283 (Pubitemid 40309309)
40. Gravalos C, Marquez A, Garcia-Carbonero R, et al.: Correlation between Her2/neu overexpression/amplification and clinicopathological parameters in advanced gastric cancer patients: a prospective study [abstract 89]. Presented at the 2007 Gastrointestinal Cancers Symposium. Orlando, FL; January 19-21, 2007.
41. Kang Y, Bang Y, Lordick F, et al.: Incidence of gastric and gastro-esophageal cancer in the ToGA trial: correlation with HER2 positivity [abstract 11]. Presented at the 2008 Gastrointestinal Cancers Symposium. Orlando, FL; January 25-27, 2008.
42. •• Van Cutsem E, Kang Y, Chung H, et al.: Efficacy results from the ToGA trial. A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER-2)-positive advanced gastric cancer (GC). J Clin Oncol (Meeting Abstracts) 2009, 27:LBA4509. This is the first phase 3 randomized clinical trial demonstrating a survival advantage with the addition of a molecularly targeted agent (trastuzumab) to standard chemotherapy in gastric cancer patients.
43. MA Shan RK Ramanathan DH Ilson, et al. 2006 Multicenter phase II study of irinotecan, cisplatin and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma J Clin Oncol 24 5201 5206 10.1200/JCO.2006.08.0887 (Pubitemid 46631363)
44. D Kelsen M Jhawer D Ilson, et al. 2009 Analysis of survival with modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma: Results of a phase II clinical trial J Clin Oncol (Meeting Abstracts) 27 4512
45. BF El-Rayes B Patel M Zalupski, et al. 2009 A phase II study of bevacizumab, docetaxel, and oxaliplatin in gastric and GEJ cancer J Clin Oncol (Meeting Abstracts) 27 4563
46. W Sun ME Powell P O'Dwyer, et al. 2009 A phase II study: Combination of sorafenib with docetaxel and cisplatin in the treatment of metastatic or advanced unresectable gastric and gastroesophageal junction (GEJ) adenocarcinoma (ECOG 5203) J Clin Oncol (Meeting Abstracts) 26 4535
47. C Kim J Lee Y Choi, et al. 2009 Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer J Clin Oncol (Meeting Abstracts) 26 4559
48. M Jhawer HL Kindler Z Wainberg, et al. 2009 Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II study J Clin Oncol (Meeting Abstracts) 26 4502
49. Yamada Y, Doi T, Muro K, et al.: Multicenter phase II study of everolimus in patients with treated metastatic gastric cancer: main results. In Proceedings of the American Society of Clinical Oncology 2009; Gastrointestinal Cancer Symposium. Abstract 77.